Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 6/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.37 |
| ▸ | SGK1 | O00141 | 1/20 | 0.35 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.33 |
| ▸ | JAK3 | P52333 | 3/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | JAK1 | P23458 | 1/20 | 0.32 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.32 |
| ▸ | BTK | Q06187 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | PLK4 | O00444 | 4/20 | 0.31 |
| ▸ | PAK4 | O96013 | 3/20 | 0.31 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12801991 | 0.87 | LRRK2 (0.42) | LRRK2CYP1A2JAK3JAK2JAK1 | |
| SCHEMBL1662522 | 0.73 | PTK6 (0.42) | LRRK2CYP1A2JAK3PTK6PLK4 | |
| SCHEMBL12801967 | 0.71 | LRRK2 (0.41) | LRRK2CYP1A2CREBBPJAK3JAK2 | |
| SCHEMBL4542875 | 0.69 | LRRK2 (0.59) | LRRK2CYP1A2 | |
| SCHEMBL1664797 | 0.66 | LRRK2 (0.36) | LRRK2CYP1A2JAK2JAK1PLK4 | |
| SCHEMBL1662570 | 0.64 | LRRK2 (0.42) | LRRK2PLK4PAK4HTR2AHTR2C | |
| SCHEMBL12801929 | 0.64 | LRRK2 (0.44) | LRRK2CYP1A2CREBBPJAK3JAK2 | |
| SCHEMBL1665604 | 0.63 | LRRK2 (0.48) | LRRK2CYP1A2CREBBPJAK3JAK2 | |
| SCHEMBL1662494 | 0.62 | SGK1 (0.34) | SGK1HTR2AHTR2C | |
| SCHEMBL1662412 | 0.61 | PAK4 (0.45) | LMNATP53PLK4PAK4HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9242987-B2 | Heterocyclyl pyrazolopyrimidine analogues as JAK inhibitors | CELLZOME LIMITED (GB) | 2016-01-26 | — | — | US | disclosed |
| US-20120252779-A1 | HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS JAK INHIBITORS | CELLZOME LIMITED (GB) | 2012-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120252779-A1 | HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS JAK INHIBITORS | JAK1, JAK3, JAK2 | LRRK2 2904/4885CYP1A2 592/4885SGK1 1537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.